Navigation Links
CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011
Date:4/19/2011

er and glioblastoma.

CureFAKtor recently received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options, and is planning a Phase I clinical study in 2012.

"Focal Adhesion Kinase protein binding inhibitors, such as CFAK-C4, represent a promising area of research as FAK is expressed at extremely high levels in solid cancer tumors and serves as a survival mechanism by signaling tumor growth, invasion and metastasis," said H. Shep Wild.  "We have strong ties to the University of Florida Shands Cancer Center and we look forward to progressing this important research in order to help cancer patients."

CureFAKtor CFAK-C4 Research Results

CureFAKtor recently presented preclinical research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.  

In a poster presentation, CureFAKtor reported that the study pinpointed the site of interaction of VEGFR-3 and FAK to create small molecule drugs capable of disrupting signaling and causing death of pancreatic cancer cells.  CureFAKtor's lead compound, CFAK-C4, reduced tumor growth in vivo in mouse pancreatic cancer cells by up to 60 percent, and CFAK-C4 combined with chemotherapy drug gemcitabine had a synergistic effect and led to 80 percent pancreatic cancer tumor reduction.  

The study also found that CFAK-C4 combined with gemcitabine had a prolonged effect on pancreatic tumor growth.  Two weeks after treatment, the tumor size in the previously treated group was approximately 75 percent smaller than
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... The latest addition to the ... prints and verifies labels automatically. Companies in the pharmaceutical and healthcare industry can use ... to 500 per minute. The Label Serialization Station can be fully integrated into the ...
(Date:9/3/2015)... - bioLytical Laboratories Inc., a leader in rapid diagnostic ... of a rapid point of care assay for early ... HIV gp41 IgM antibodies " has been published in ... ability to detect early HIV infection.  ... annual International AIDS Society Conference, which highlighted early ...
(Date:9/3/2015)... ... September 03, 2015 , ... Michigan-based technology startup Halo ... , The device, called the Halo H1, is a wearable that monitors ... These sensors track trending interstitial fluid levels in the body, in addition to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... systems, analytical testing, education and consulting services for the medical device sector, ... products/processes development, design control, validation, quality assurance and regulatory compliance. Avarent will ...
Breaking Biology Technology:Print and Verify Labels On The Production Line With New Label Serialization Stations 2Print and Verify Labels On The Production Line With New Label Serialization Stations 3bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7
... Silence Therapeutics plc (London AIM:,SLN), a leading ... the successful opposition of a fundamental Alnylam,Pharmaceuticals, Inc. ... its entirety., The Opposition Division of the ... its decision to revoke European Patent EP 1,230 ...
... First-in-Man study success, Ovalum Ltd. launches a multicenter study using ... privately held Israeli medical device company, has announced today successful ... in the coronary arteries. , ... ...
... European Molecular Biology Laboratory (EMBL) discovered a new way to ... computational method that compares how similar the side effects of ... on the same target molecule. The study, published in ... drugs. , Similar drugs often share target proteins, modes of ...
Cached Biology Technology:Silence Therapeutics Announces Successful Opposition of Glover Patent 2Silence Therapeutics Announces Successful Opposition of Glover Patent 3Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire 2Teaching old drugs new tricks 2
(Date:8/31/2015)... , August 31, 2015 ... biometrics technology in government digitization projects to drive ... a recently published TechSci Research report, " India Biometrics Market ... India is projected to grow at a CAGR ... market is anticipated on account of extensive use of biometric ...
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... VIEW, Calif. , Aug. 24, 2015  Based on ... Sullivan recognizes DERMALOG with the 2015 African Biometrics Company of ... and has achieved substantial commercial success in Africa ... Nigeria , where it has implemented one of the ... 23 banks as well as the Central Bank of ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6
... The December issue of the Journal of the ... the everyday eating habits of consumers. Researchers look at ... choice and methods for adding healthier foods to a ... 2008 Journal of the American Dietetic Association include ...
... Permission has been granted to start the first safety ... ALS. ALS is an incurable, paralyzing neurodegenerative disorder that ... affects healthy people in the most active period of ... the K.U.Leuven have previously shown the possibilities for the ...
... A stunning discovery based on epigenetics (the inheritance of ... nutrient found in eggs and other foodsduring pregnancy may ... This finding by a team of biologists at Boston ... pregnancy to breast cancer. It also is the first ...
Cached Biology News:News from the December 2008 Journal of the American Dietetic Association 2First trial in patients with a potential treatment of the incurable ALS muscle disease 2First trial in patients with a potential treatment of the incurable ALS muscle disease 3Eating eggs when pregnant affects breast cancer in offspring 2
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Rice microRNA Microarray ...
... spectrofluorometer with a minimum 1 nm resolution ... or greater for the Raman band of ... keep in mind in order to meet ... or anisotropic measurements. ,The FP-6500 is designed ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
Biology Products: